Q-omics provides the consensus-scored NCK2 profile across patient tissues and cancer cell-line models. NCK2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NCK2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, NCK2 protein abundance shows 22,510 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, and PDAC as cancer lineages where NCK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCK2 survival associations across molecular data types. NCK2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCK2 RNA expression–survival associations across cancer types. High NCK2 expression shows unfavorable associations in MESO, KICH, ACC and LGG, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NCK2 RNA expression.
This table summarizes NCK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NCK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCK2 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, CHOL, LIHC and LUSC. The KIRC box plot shows higher NCK2 RNA expression in tumor versus normal tissue (log2 FC = +1.126, t-test p < 0.001).
This table shows molecular features associated with NCK2 in patient tissues and cancer cell lines. In patient samples, NCK2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, NCK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
